Eluxadoline Availability in India
Eluxadoline (Viberzi) is not approved or available in India, as it has only received FDA approval in the United States and is not registered with the Central Drugs Standard Control Organisation (CDSCO) for use in the Indian market.
Background on Eluxadoline
Eluxadoline is a mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults 1. The 2022 AGA guidelines conditionally recommend its use in IBS-D patients with moderate certainty of evidence 2.
Standard Dosing (if it were available):
- Primary dose: 100 mg twice daily with food 1
- Reduced dose (75 mg twice daily) for patients who:
- Cannot tolerate 100 mg
- Have mild-moderate hepatic impairment (Child-Pugh A or B)
- Have moderate-severe renal impairment (eGFR <60 mL/min/1.73 m²)
- Are taking OATP1B1 inhibitors 1
Critical Contraindications:
Absolute contraindications include 1:
- Absence of gallbladder (highest risk for pancreatitis and sphincter of Oddi spasm)
- Alcohol consumption >3 drinks/day or alcohol abuse/addiction
- History of pancreatitis or pancreatic duct obstruction
- Biliary duct obstruction or sphincter of Oddi dysfunction
- Severe hepatic impairment (Child-Pugh C)
- History of chronic/severe constipation or mechanical GI obstruction
Serious Adverse Events:
The drug carries significant risks 2:
- Pancreatitis: 3 more cases per 1000 patients (high certainty evidence)
- Sphincter of Oddi dysfunction: 5 more cases per 1000 patients (high certainty evidence)
- Fatal cases reported in patients without gallbladders 1
- Most common side effects: constipation (8%), nausea (7%), abdominal pain (7%) 2
Alternative Therapies for IBS-D in India
Since eluxadoline is unavailable, consider this treatment algorithm:
First-Line Options:
1. Rifaximin (if available in India):
- Non-absorbable antibiotic with proven efficacy
- Dosing: 550 mg three times daily for 14 days
- Can be repeated for up to two additional courses 3, 4
- Lower risk profile than eluxadoline
- Moderate certainty evidence for symptom relief 2
2. Dietary modifications:
- Reduce caffeine and alcohol intake
- Increase soluble fiber intake
- Adequate hydration 5
3. Loperamide (over-the-counter):
- Improves stool frequency and rectal urgency
- Mixed results for abdominal pain 5
- Widely available and inexpensive
Second-Line Options:
4. Tricyclic antidepressants (off-label):
- Effective for abdominal pain modulation
- Low-dose amitriptyline or nortriptyline 5
5. Bile acid sequestrants:
- Particularly useful if bile acid diarrhea suspected
- Cholestyramine is commonly available 5
6. Antispasmodics:
- For cramping and urgency
- Various agents available in India 5
Third-Line Option:
7. Alosetron (if available):
- 5-HT3 receptor antagonist
- Requires careful monitoring due to ischemic colitis risk 4, 6
- Restricted use program in some countries
Clinical Pearls:
- Eluxadoline works best for predominant diarrhea rather than predominant abdominal pain 2
- Efficacy data shows 27.2% vs 16.7% FDA endpoint responders (eluxadoline vs placebo) - a modest but significant benefit 2
- The absence of a gallbladder is the single most important risk factor for serious complications 1, 7
- Always screen for alcohol use before considering any opioid-based therapy 1
Common Pitfalls to Avoid:
- Do not attempt to import eluxadoline without proper regulatory approval
- Do not use in post-cholecystectomy patients even if the drug becomes available
- Screen for structural pancreatic or biliary disease before initiating therapy
- Monitor for severe constipation and discontinue if it develops 1
The most practical approach in India is to utilize rifaximin as the closest evidence-based alternative, combined with dietary modifications and symptomatic management with loperamide or antispasmodics as needed.